Adaptive Anti-MICA Antigen Binding Fragments for Specialized Environments

The present inventive concept relates to specialized variations of anti-MICA antigen binding fragments, fusion molecules, and cells that express them, designed for high-security biotechnology research facilities, disaster relief, extreme weather conditions, and remote or isolated areas.

The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, and cells that express them, but lacked adaptations for specific, narrow markets or unique operational environments. The present inventive concept addresses this limitation by providing specialized variations that cater to high-security needs, disaster relief, extreme weather conditions, and remote or isolated areas, ensuring targeted and effective immune responses in these contexts.

The new inventive concept encompasses a system for high-security biotechnology research facilities, comprising a polynucleotide encoding an anti-MICA chimeric antigen receptor (CAR) designed to minimize cross-reactivity with non-target cells. Additionally, the concept includes a method for disaster relief, involving the administration of a composition comprising a polynucleotide encoding an anti-MICA CAR engineered to provide rapid and targeted immune response in emergency situations. Furthermore, a bi-specific T-cell engager is disclosed for use in extreme weather conditions, comprising a fusion protein with two different single-chain variable fragments (scFvs), one binding to MICA and the other to an immune cell target, and formulated to maintain stability and potency in high-temperature or high-humidity environments. A kit for high-security biotechnology research facilities and a system for remote or isolated areas are also described, comprising a portable device for administering a composition comprising a polynucleotide encoding an anti-MICA CAR, designed to operate in extreme weather conditions and provide real-time monitoring of the subject's immune response.

The new claims introduce novel adaptations of anti-MICA antigen binding fragments, fusion molecules, and cells that express them, specifically designed for high-security biotechnology research facilities, disaster relief, extreme weather conditions, and remote or isolated areas. These specialized variations demonstrate a non-obvious improvement over the original patent, providing targeted and effective immune responses in unique operational environments.

Alternative embodiments of the inventive concept could include adaptations for other specialized environments, such as space exploration or high-altitude research. Variations of the bi-specific T-cell engager could be designed for use in different temperature or humidity ranges, or with different immune cell targets. The kit and system for remote or isolated areas could be modified for use in different types of emergency situations or for administering different compositions.

The present inventive concept has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of high-security research, disaster relief, and extreme environment operations. The market for specialized immune therapies is growing, and the inventive concept's adaptations for unique operational environments position it for significant market share and revenue growth.